Horizon Blue Cross Blue Shield of New Jersey has been involved in a number of value-based cancer care initiatives that will be highlighted during an upcoming Asembia session, said Steven Peskin, MD, MBA, executive director, director of population health, Horizon Blue Cross Blue Shield of New Jersey.
Horizon Blue Cross Blue Shield of New Jersey has been involved in a number of value-based cancer care initiatives that will be highlighted during an upcoming Asembia session, said Steven Peskin, MD, MBA, executive director, director of population health, Horizon Blue Cross Blue Shield of New Jersey.
Transcript
Can you provide a sneak peek of some of your key talking points at Asembia?
I'll be talking about things that we've been doing and value-based cancer care, and certainly that covers a fairly broad expanse. We've been involved with a number of our oncology clinical partners at Horizon Blue Cross Blue Shield of New Jersey, with shared savings and moving into shared risk. We worked in non–small cell lung cancer, breast cancer, prostate, non-Hodgkin’s lymphoma, colorectal, among others. And so that's what I'll be highlighting.
We also had an oncology medical home model, which was partly benchmarked from Dr. [Barbara] McAneny’s work and Dr. [John] Sprandio’s work and had some elements of the OCM [Oncology Care Model]—we did not formally participate in the OCM, and we’re, as a company, in the very early stages and some of the preliminary discussions around Capitol Hill on the OCM. But we elected to go our own way with our own value payment models and oncology medical home.
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More